Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Mediators Inflamm ; 2019: 6481812, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31049025

RESUMO

Clinically active drugs for the treatment of acute pain have their prescription limited due to the significant side effects they induce. An increase in reactive oxygen species (ROS) has been linked to several conditions, including inflammation and pain processing. Therefore, new or repurposed drugs with the ability of reducing ROS-triggered responses are promising candidates for analgesic drugs. Vinpocetine is a clinically used nootropic drug with antioxidant, anti-inflammatory, and analgesic properties. However, the effects of vinpocetine have not been investigated in a model with a direct relationship between ROS, inflammation, and pain. Based on that, we aimed to investigate the effects of vinpocetine in a model of superoxide anion-induced pain and inflammation using potassium superoxide (KO2) as a superoxide anion donor to trigger inflammation and pain. In the KO2 model, vinpocetine dose-dependently reduced pain-like behaviors (spontaneous pain and hyperalgesia), paw edema, and neutrophil and mononuclear cell recruitment to the paw skin (assessed by H&E staining, fluorescence, and enzymatic assays) and to the peritoneal cavity. Vinpocetine also restored tissue endogenous antioxidant ability and Nrf2 and Ho-1 mRNA expression and reduced superoxide anion production and gp91phox mRNA expression. We also observed the inhibition of IκBα degradation by vinpocetine, which demonstrates a reduction in the activation of NF-κB explaining the diminished production of IL-33, IL-1ß, and TNF-α. Collectively, our data show that vinpocetine alleviates pain and inflammation induced by KO2, which is a mouse model with a direct role of ROS in triggering pain and other inflammatory phenomena. Thus, the results suggest the repurposing of vinpocetine as an anti-inflammatory and analgesic drug.


Assuntos
Analgésicos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Reposicionamento de Medicamentos/métodos , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Nootrópicos/uso terapêutico , Superóxidos/toxicidade , Alcaloides de Vinca/uso terapêutico , Animais , Citocinas/metabolismo , Modelos Animais de Doenças , Edema/tratamento farmacológico , Edema/metabolismo , Heme Oxigenase-1 , Hiperalgesia/tratamento farmacológico , Hiperalgesia/metabolismo , Masculino , Proteínas de Membrana , Camundongos , Fator 2 Relacionado a NF-E2/genética , Fator 2 Relacionado a NF-E2/metabolismo , NF-kappa B/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo
2.
Biomed Res Int ; 2017: 9584819, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28589150

RESUMO

The present study evaluated the anti-inflammatory and analgesic effects of the superoxide dismutase mimetic agent tempol in superoxide anion-induced pain and inflammation. Mice were treated intraperitoneally with tempol (10-100 mg/kg) 40 min before the intraplantar injection of a superoxide anion donor, potassium superoxide (KO2, 30 µg). Mechanical hyperalgesia and thermal hyperalgesia, paw edema, and mRNA expression of peripheral and spinal cord mediators involved in inflammatory pain, TNFα, IL-1ß, IL-10, COX-2, preproET-1, gp91phox, Nrf2, GFAP, and Iba-1, were evaluated. Peripheral and spinal cord reductions of antioxidant defenses and superoxide anion were also assessed. Tempol reduced KO2-induced mechanical hyperalgesia and thermal hyperalgesia and paw edema. The increased mRNA expression of the evaluated mediators and oxidative stress in the paw skin and spinal cord and increased mRNA expression of glial markers in the spinal cord induced by KO2 were successfully inhibited by tempol. KO2-induced reduction in Nrf2 mRNA expression in paw skin and spinal cord was also reverted by tempol. Corroborating the effect of tempol in the KO2 model, tempol also inhibited carrageenan and CFA inflammatory hyperalgesia. The present study demonstrates that tempol inhibits superoxide anion-induced molecular and behavioral alterations, indicating that tempol deserves further preclinical studies as a promising analgesic and anti-inflammatory molecule for the treatment of inflammatory pain.


Assuntos
Materiais Biomiméticos/farmacologia , Óxidos N-Cíclicos/farmacologia , Dor , Superóxido Dismutase , Superóxidos/metabolismo , Animais , Proteínas de Ligação ao Cálcio/metabolismo , Ciclo-Oxigenase 2/metabolismo , Citocinas/metabolismo , Proteína Glial Fibrilar Ácida/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Proteínas dos Microfilamentos/metabolismo , NADPH Oxidase 2/metabolismo , Fator 2 Relacionado a NF-E2/metabolismo , Dor/tratamento farmacológico , Dor/metabolismo , Dor/patologia , Marcadores de Spin
3.
Anal Cell Pathol (Amst) ; 2015: 285708, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26351625

RESUMO

Cancer pain directly affects the patient's quality of life. We have previously demonstrated that the subcutaneous administration of the mammary adenocarcinoma known as Ehrlich tumor induces pain in mice. Several studies have shown that the flavonoid quercetin presents important biological effects, including anti-inflammatory, antioxidant, analgesic, and antitumor activity. Therefore, the analgesic effect and mechanisms of quercetin were evaluated in Ehrlich tumor-induced cancer pain in mice. Intraperitoneal (i.p.) treatments with quercetin reduced Ehrlich tumor-induced mechanical and thermal hyperalgesia, but not paw thickness or histological alterations, indicating an analgesic effect without affecting tumor growth. Regarding the analgesic mechanisms of quercetin, it inhibited the production of hyperalgesic cytokines IL-1ß and TNFα and decreased neutrophil recruitment (myeloperoxidase activity) and oxidative stress. Naloxone (opioid receptor antagonist) inhibited quercetin analgesia without interfering with neutrophil recruitment, cytokine production, and oxidative stress. Importantly, cotreatment with morphine and quercetin at doses that were ineffective as single treatment reduced the nociceptive responses. Concluding, quercetin reduces the Ehrlich tumor-induced cancer pain by reducing the production of hyperalgesic cytokines, neutrophil recruitment, and oxidative stress as well as by activating an opioid-dependent analgesic pathway and potentiation of morphine analgesia. Thus, quercetin treatment seems a suitable therapeutic approach for cancer pain that merits further investigation.


Assuntos
Carcinoma de Ehrlich/complicações , Dor/tratamento farmacológico , Dor/etiologia , Quercetina/uso terapêutico , Analgésicos/farmacologia , Analgésicos/uso terapêutico , Analgésicos Opioides/farmacologia , Animais , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Comportamento Animal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Feminino , Interleucina-1beta/biossíntese , Masculino , Camundongos , Morfina/farmacologia , Morfina/uso terapêutico , Naloxona/farmacologia , Naloxona/uso terapêutico , Infiltração de Neutrófilos/efeitos dos fármacos , Estresse Oxidativo , Dor/patologia , Quercetina/farmacologia , Pele/patologia , Medula Espinal/patologia , Fator de Necrose Tumoral alfa/biossíntese
4.
Biomed Res Int ; 2013: 624815, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24073414

RESUMO

The Ehrlich tumor is a mammary adenocarcinoma of mice that can be developed in solid and ascitic forms depending on its administration in tissues or cavities, respectively. The present study investigates whether the subcutaneous plantar administration of the Ehrlich tumor cells induces pain-like behavior and initial pharmacological susceptibility characteristics. The Ehrlich tumor cells (1 × 10(4)-10(7) cells) induced dose-dependent mechanical hyperalgesia (electronic version of the von Frey filaments), paw edema/tumor growth (caliper), and flinches compared with the saline group between days 2 and 12. There was no difference between doses of cells regarding thermal hyperalgesia in the hot-plate test. Indomethacin (a cyclooxygenase inhibitor) and amitriptyline hydrochloride (a tricyclic antidepressant) treatments did not affect flinches or thermal and mechanical hyperalgesia. On the other hand, morphine (an opioid) inhibited the flinch behavior and the thermal and mechanical hyperalgesia. These effects of morphine on pain-like behavior were prevented by naloxone (an opioid receptor antagonist) treatment. None of the treatments affected paw edema/tumor growth. The results showed that, in addition to tumor growth, administration of the Ehrlich tumor cells may represent a novel model for the study of cancer pain, specially the pain that is susceptible to treatment with opioids, but not to cyclooxygenase inhibitor or to tricyclic antidepressant.


Assuntos
Comportamento Animal , Carcinoma de Ehrlich/tratamento farmacológico , Carcinoma de Ehrlich/fisiopatologia , Avaliação Pré-Clínica de Medicamentos , Dor/tratamento farmacológico , Dor/fisiopatologia , Amitriptilina/farmacologia , Amitriptilina/uso terapêutico , Animais , Comportamento Animal/efeitos dos fármacos , Carcinoma de Ehrlich/complicações , Carcinoma de Ehrlich/patologia , Proliferação de Células/efeitos dos fármacos , Modelos Animais de Doenças , Edema/complicações , Edema/tratamento farmacológico , Edema/patologia , Hiperalgesia/patologia , Hiperalgesia/fisiopatologia , Indometacina/farmacologia , Indometacina/uso terapêutico , Masculino , Camundongos , Morfina/farmacologia , Morfina/uso terapêutico , Transplante de Neoplasias , Nociceptividade/efeitos dos fármacos , Dor/etiologia , Tela Subcutânea/patologia , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA